Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Oct 31;77(5):1873-1879.
doi: 10.22092/ARI.2022.358193.2173. eCollection 2022 Oct.

The Preoperative Serum Levels of the Anaphylatoxins C3a and C5a and Their Association with Clinico-Pathological Factors in Breast Cancer Patients

B H Hameed  1 , I Abdulsatar Al-Rayahi  2 , S S Muhsin  3
Affiliations

The Preoperative Serum Levels of the Anaphylatoxins C3a and C5a and Their Association with Clinico-Pathological Factors in Breast Cancer Patients

B H Hameed et al. Arch Razi Inst. .

Abstract

Breast cancer is a common women malignancy worldwide. Emerging evidence suggests that various complement molecules function as an immune suppressors in the tumor microenvironment (TME). Therefore this study aimed to investigate the role of the anaphylatoxins C3a and C5a in the propagation of breast cancer and their relationships with clinicopathological factors in Iraqi women suffering from breast tumors. ELISA technique was used to determine the serum anaphylatoxins C3a and C4a levels in 60 Iraqi women with breast tumors (30 with primary breast cancer and 30 with benign breast tumor) before surgery and treatment as 30 healthy controls. In addition, the clinicopathological factors of all the patients were collected. The result showed a significantly increased level of anaphylatoxins C3a and C5a (P<0.001) in primary breast cancer patients than in benign breast tumor and healthy control women. The area under the curve (AUC) of C3a and C5a for distinguishing patients with primary breast cancer and healthy control subjects was 0.878 (95% CI: 0.768 to 0.948) and 0.953 (95% CI: 0.865 to 0.991) respectively. C5a correlated with larger tumor size, lymph node metastasis, and histologic grade III, whereas C3a only with lymph node metastasis. In conclusion, preoperative levels of C5a exhibit high accuracy for primary breast cancer than C3a. C5a correlated with tumor burden more than C3a and suggested an enhancing effect of C5a on BC proliferation. Thus, suggesting prognostic value for C5a in primary BC.

Keywords: Clinico-pathological factors; Breast cancer; C3a; C5a; Prognosis.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no conflict of interest.

Figures

Figure 1
Figure 1
The preoperative serum levels of C3a and C5a in study groups
Figure 2
Figure 2
The receiver operating characteristic curve was constructed to evaluate the immunological parameters C3a and C5a for breast cancer. (A & B) for distinguishing patients with primary breast cancer and patients with benign breast tumor; (C & D) for distinguishing patients with primary breast cancer and healthy control subjects
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Siegel RL, Miller KD, Goding Sauer A, Fedewa SA, Butterly LF, Anderson JC, et al. Colorectal cancer statistics, 2020. Cancer J Clin. 2020;70(3):145–64. - PubMed
    1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. Cancer J Clin. 2018;68(6):394–424. - PubMed
    1. Merle NS, Church SE, Fremeaux-Bacchi V, Roumenina LT. Complement system part I–molecular mechanisms of activation and regulation. Front Immunol. 2015;6:262. - PMC - PubMed
    1. Klos A, Wende E, Wareham KJ, Monk PN. International union of basic and clinical pharmacology. LXXXVII. Complement peptide C5a, C4a, and C3a receptors Pharmacol Rev 2013;65(1):500–43. - PubMed
    1. Wang Y, Zhang H, He Y-W. The complement receptors C3aR and C5aR are a new class of immune checkpoint receptor in cancer immunotherapy. Front Immunol. 2019;10:1574. - PMC - PubMed